SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer: meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis.Oncotarget · 2017Pooled it
- Meta-Analysis of Prognostic and Clinical Significance of CD44v6 in Esophageal Cancer.Medicine · 2015Pooled it
- Exploring the Functional Consequences of Protein-Coding Alternative Splice Variants at a Genome Scale: A Guide to Utilizing EXPANSION.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Digging into the Solubility Factor in Cancer Diagnosis: A Case of Soluble CD44 Protein.Biosensors · 2025Review
- Biological implications of decoding the extracellular matrix of vulva cancer.Oncology reports · 2025Review
- CD44 targeted functionalized nanocarriers for non-small cell lung cancer.Frontiers in oncology · 2025Review
- A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment.Journal of experimental & clinical cancer research : CR · 2024Article
- Immunomodulatory Gene-Splicing Dysregulation in Tumorigenesis: Unmasking the Complexity.Molecules (Basel, Switzerland) · 2023Review
- The clinical significance of CD44v6 in malignant and benign primary bone tumors.BMC musculoskeletal disorders · 2023Article
- EXPANSION: a webserver to explore the functional consequences of protein-coding alternative splice variants in cancer genomics.Bioinformatics advances · 2023Article
- Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study.Oncotarget · 2022Article
- Ionizing Radiation Promotes Epithelial-Mesenchymal Transition Phenotype and Stem Cell Marker in The Lung adenocarcinoma: In Vitro and Bioinformatic Studiesc.Cell journal · 2022Article
- CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.International journal of molecular sciences · 2022Article
- Endoscopic Applications of Near-Infrared Photoimmunotherapy (NIR-PIT) in Cancers of the Digestive and Respiratory Tracts.Biomedicines · 2022Review
- Article
- Overexpression of CD44v8-10 in Colon Polyps-A Possible Key to Early Diagnosis.Pathology oncology research : POR · 2021Article
- CD44 in Ovarian Cancer Progression and Therapy Resistance-A Critical Role for STAT3.Frontiers in oncology · 2020Review
- CD44v6 engages in colorectal cancer progression.Cell death & disease · 2019Review
- Therapeutic Strategies Targeting Cancer Stem Cells and Their Microenvironment.Frontiers in oncology · 2019Review
- AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer.JCI insight · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to clarify the prognostic value of CD44 in survival of patients with non-small cell lung cancer (NSCLC). We performed a meta-analysis of relevant literature to aggregate the available survival results, using studies published in English until March 2014. Eligible studies dealt with CD44, CD44 standard form (CD44s) and CD44 variant 6 (CD44v6), assessment in NSCLC patients on primary lesions and reported survival data according to CD44 and CD44 isoforms expression. We aggregated 10 trials (5 trials for CD44v6, 3 trials for CD44, and 2 trials for CD44s) comprising 1,074 patients, in this meta-analysis. The combined hazard ratio (HR) with CD44v6 and CD44s was 2.39 (95 % confidence interval (CI) 1.69-3.37) and 1.64 (95 % CI 1.06-2.52), respectively. It associated high CD44v6 and CD44s expression with poor survival in NSCLC patients. However, CD44 overexpression did not significantly correlate with survival in patients with NSCLC (HR 1.44; 95 % CI 0.72-2.89). Our meta-analysis shows that CD44v6 and CD44s overexpression indicates poor prognosis for NSCLC patients. However, the high CD44 expression is not significantly correlated with survival for patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.